Post-Market Clinical Study to Evaluate the Safety and Effectiveness of REFLEX ULTRA 45 for Coblation Inferior Turbinate Reduction in China

NCT ID: NCT07025304

Last Updated: 2026-01-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

105 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-07-02

Study Completion Date

2028-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is a prospective, multi-center, post-market clinical study to evaluate the safety and effectiveness of REFLEX ULTRA 45 for the coblation inferior turbinate reduction in China. The study product is REFLEX ULTRA 45 (EIC4845-01/EICA4845-01). Also it needs to be performed with the controller system COBLATOR II or WEREWOLF. The sample size is 105 subjects with approximate 6 sites in China mainland.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Inferior turbinate hypertrophy (ITH) is a common condition characterized by the enlargement of the inferior turbinate which is mainly due to swelling of the sub-mucosa and rarely due to enlargement of the bone itself. Based on current studies, there are several surgical techniques is being widely used in clinic for ITH includes turbinectomy, electrocautery, laser surgery, cryotherapy, Microdebrider-assisted inferior turbinoplasty (MAIT) and radiofrequency ablation (RFA). The technique used in this study for ITH is Coblation produced by REFLEX ULTRA 45. With limited high quality literature in Chinese population, it is the main purpose to generate high quality evidence among the Chinese population to establish the effectiveness and safety in Chinese population with sufficient outcomes evaluation and appropriate inclusion and exclusion criteria.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nasal Obstruction Due to Inferior Turbinate Hypertrophy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

REFLEX ULTRA 45

The investigational product REFLEX ULTRA 45 includes two models which are EIC4845-01 and EICA4845-01. The only difference between these two models is the EICA4845-01 has a maximum two-use limit.

Group Type EXPERIMENTAL

REFLEX ULTRA 45

Intervention Type DEVICE

One time use for surgery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

REFLEX ULTRA 45

One time use for surgery

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject with at least two-year history of perennial rhinitis and who has failed one month of continuous standardized treatment with hormonal nasal spray by the date of surgery.
* Subject with nasal obstruction due to turbinate hypertrophy and is suitable to receive coblation inferior turbinate reduction for bilateral nasal cavity without outfracture of inferior turbinate per the investigator's judgement.
* Subject is 18 - 65 years old (inclusive).
* Subject provides written informed consent for study participation using an Independent Ethical Committee (IEC) approved consent form before any study procedures are performed, including pre- operative data review and/or collection of data on electronic Case Report Forms (eCRFs).
* Subject is willing and able to participate in required follow-up visits and is able to complete study activities.

Exclusion Criteria

* Subject who does not meet the indication or is contraindicated according to specific REFLEX ULTRA 45 's Instructions for Use (IFUs).
* Subject with obvious deviation of nasal septum with the necessity of surgery under investigator's judgement.
* Participation in the treatment period of another clinical trial within thirty (30) days of all visits completed.
* Subject who needs other nasal surgery other than single inferior turbinate reduction evaluated by MRI and nasal endoscopy.
* Subject who has nasal obstruction due to inferior turbinate bony hypertrophy.
* Subject who was treated with inferior turbinate reduction before informed consent.
* Subjects who completed the Zung Self-Rating Anxiety Scale and the anxiety rate is more than 59.
* Woman who is pregnant, nursing, or of child-bearing potential who are not utilizing highly effective birth control measures.
* Any subject that meets the definition of a Vulnerable Subject per ISO 14155 Section 3.55.
* Subject who has participated previously in this clinical trial or who has been withdrawn.
* Subject with a history of poor compliance with medical treatment.
* Subject with a medical or physical condition that, in the opinion of the Investigator, would preclude safe subject participation in the study.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Smith & Nephew, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dongdong Zhu

Role: PRINCIPAL_INVESTIGATOR

China-Japan Union Hospital, Jilin University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The First Affiliated Hospital, Sun Yat-sen University

Guangzhou, Guangdong, China

Site Status RECRUITING

The Third Affiliated Hospital, Sun Yat-sen University

Guangzhou, Guangdong, China

Site Status RECRUITING

Henan Provincial People's Hospital

Zhengzhou, Henan, China

Site Status RECRUITING

Jiangsu Province Hospital

Nanjing, Jiangsu, China

Site Status RECRUITING

China-Japan Union Hospital of Jilin University

Changchun, Jilin, China

Site Status RECRUITING

Sir Run Run Shaw Hospital Affiliated with Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Cathy Xiao

Role: CONTACT

+86 18221637315

Julian Yang

Role: CONTACT

+86 18101802151

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jian Li

Role: primary

020-87608412

Ointai Yang

Role: primary

020-85252131

Guangke Wang

Role: primary

Role: backup

0371-87160070

Lei Cheng

Role: primary

025-68303974

Dongdong Zhu

Role: primary

0431-89876991

Mang Xiao

Role: primary

0571-86006065

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SNIS-E-1198

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.